Finnton Logo
VTRS

Viatris Inc

VTRS, USA

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

https://www.viatris.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.12

Next Payout:

Dec 15, 2025

Yield:

4.1202 %

Discipline and Rules-Based Execution in VTRS Response - news.stocktradersdaily.com

12/12/2025

VTRS
stock
VTRS

Discipline and Rules-Based Execution in VTRS Response news.stocktradersdaily.com

Read more →

Barclays Upgrades Viatris(VTRS.US) to Buy Rating, Raises Target Price to $15 - 富途牛牛

12/8/2025

VTRS
stock
VTRS

Barclays Upgrades Viatris(VTRS.US) to Buy Rating, Raises Target Price to $15 富途牛牛

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$12.125

Analyst Picks

Strong Buy

2

Buy

1

Hold

5

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.89

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.84 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.34 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

17.16 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.49

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 83.58% of the total shares of Viatris Inc

1.

Vanguard Group Inc

(12.4469%)

since

2025/06/30

2.

BlackRock Inc

(7.1072%)

since

2025/06/30

3.

T. Rowe Price Associates, Inc.

(6.7565%)

since

2025/06/30

4.

Davis Selected Advisers

(5.6932%)

since

2025/06/30

5.

State Street Corp

(4.7422%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(3.1856%)

since

2025/07/31

7.

Dimensional Fund Advisors, Inc.

(2.6815%)

since

2025/06/30

8.

Geode Capital Management, LLC

(2.6784%)

since

2025/06/30

9.

Vanguard 500 Index Investor

(2.4925%)

since

2025/07/31

10.

Vanguard Small Cap Index

(2.4451%)

since

2025/07/31

11.

Amvescap Plc.

(2.3696%)

since

2025/06/30

12.

Deerfield Management Co

(2.0606%)

since

2025/06/30

13.

Ameriprise Financial Inc

(1.9861%)

since

2025/06/30

14.

Davis NY Venture A

(1.745%)

since

2025/04/30

15.

Vanguard Small Cap Value Index Inv

(1.5726%)

since

2025/07/31

16.

Invesco S&P 500® Equal Weight ETF

(1.3534%)

since

2025/08/29

17.

Morgan Stanley - Brokerage Accounts

(1.3504%)

since

2025/06/30

18.

Fidelity 500 Index

(1.2761%)

since

2025/07/31

19.

SPDR® S&P 500® ETF

(1.2187%)

since

2025/08/31

20.

iShares Core S&P 500 ETF

(1.2114%)

since

2025/08/31

21.

T. Rowe Price US Mid-Cap Value Equity

(1.127%)

since

2025/06/30

22.

T. Rowe Price Mid-Cap Value

(1.1253%)

since

2025/07/31

23.

Charles Schwab Investment Management Inc

(1.0916%)

since

2025/06/30

24.

T. Rowe Price US Lg-Cp Equity Inc Comp

(1.0593%)

since

2025/06/30

25.

T. Rowe Price Equity Income

(1.042%)

since

2025/07/31

26.

Rubric Capital Management LP

(1.0293%)

since

2025/06/30

27.

NORGES BANK

(0.9902%)

since

2025/06/30

28.

Northern Trust Corp

(0.9644%)

since

2025/06/30

29.

Bank of New York Mellon Corp

(0.8843%)

since

2025/06/30

30.

SPDR® Portfolio S&P 500® High Div ETF

(0.8244%)

since

2025/08/29

31.

Pacer Advisors, INC.

(0.8026%)

since

2025/06/30

32.

Bank of America Corp

(0.7889%)

since

2025/06/30

33.

ICICI Prudential Asset Management Company Limited

(0.7733%)

since

2025/06/30

34.

Amundi

(0.7534%)

since

2025/06/30

35.

ICICI Prudential Value Gr

(0.7451%)

since

2025/08/31

36.

Pacer US Small Cap Cash Cows 100 ETF

(0.7186%)

since

2025/08/29

37.

The Health Care Select Sector SPDR® ETF

(0.6874%)

since

2025/08/31

38.

T. Rowe Price U.S. Mid-Cap Val Eq Tr-D

(0.6354%)

since

2025/06/30

39.

Vanguard Institutional Index I

(0.6098%)

since

2025/07/31

40.

DFA US Targeted Value I

(0.5569%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.5348

Latest Release

Date

2025-09-30

EPS Actual

0.67

EPS Estimate

0.62

EPS Difference

0.05

Surprise Percent

8.0645%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7.5)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Finnton Logo

Contact us

Privacy Policy

Terms of Service

Give us Feedback